These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 23636176)
1. Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs. Kleophas W; Karaboyas A; Li Y; Bommer J; Reichel H; Walter A; Icks A; Rump LC; Pisoni RL; Robinson BM; Port FK Kidney Int; 2013 Sep; 84(3):578-84. PubMed ID: 23636176 [TBL] [Abstract][Full Text] [Related]
2. Changes in dialysis treatment modalities during institution of flat-rate reimbursement and quality assurance programs. Marcelli D; Grassmann A; Ponce P Kidney Int; 2013 Nov; 84(5):1051. PubMed ID: 24172743 [No Abstract] [Full Text] [Related]
3. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740 [TBL] [Abstract][Full Text] [Related]
4. The authors reply. Kleophas W; Karaboyas A; Li Y; Bommer J; Reichel H; Walter A; Icks A; Rump LC; Pisoni RL; Robinson BM; Port FK Kidney Int; 2013 Nov; 84(5):1051-2. PubMed ID: 24172742 [No Abstract] [Full Text] [Related]
5. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis. Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376 [TBL] [Abstract][Full Text] [Related]
6. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan. Wish JB Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798 [TBL] [Abstract][Full Text] [Related]
7. A cross-sectional study of dialysis practice-patterns in patients with chronic kidney disease on maintenance hemodialysis. Kulkarni MJ; Jamale T; Hase NK; Jagdish PK; Keskar V; Patil H; Shete A; Patil C Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):1050-6. PubMed ID: 26354590 [TBL] [Abstract][Full Text] [Related]
8. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
9. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. Fuller DS; Bieber BA; Pisoni RL; Li Y; Morgenstern H; Akizawa T; Jacobson SH; Locatelli F; Port FK; Robinson BM J Am Soc Nephrol; 2016 Jul; 27(7):2205-15. PubMed ID: 26582402 [TBL] [Abstract][Full Text] [Related]
10. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. McFarlane PA; Pisoni RL; Eichleay MA; Wald R; Port FK; Mendelssohn D Kidney Int; 2010 Jul; 78(2):215-23. PubMed ID: 20428102 [TBL] [Abstract][Full Text] [Related]
11. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion. Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770 [TBL] [Abstract][Full Text] [Related]
12. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261 [TBL] [Abstract][Full Text] [Related]
13. Cost-quality trade-offs in dialysis care: a national survey of dialysis facility administrators. Powe NR; Thamer M; Hwang W; Fink NE; Bass EB; Sadler JH; Levin NW Am J Kidney Dis; 2002 Jan; 39(1):116-26. PubMed ID: 11774110 [TBL] [Abstract][Full Text] [Related]
14. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Weinhandl ED; Gilbertson DT; Collins AJ Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009 [TBL] [Abstract][Full Text] [Related]
15. Changing patterns of anemia management in US hemodialysis patients. Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926 [TBL] [Abstract][Full Text] [Related]
16. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC). Pizzarelli F; David S; Sala P; Icardi A; Casani A Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298 [TBL] [Abstract][Full Text] [Related]